Clinical Trial

A Study to Evaluate HB0034 in Healthy Chinese Adult Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 20, 2025 (before its estimated November 20, 2025 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study is to investigate the safety and tolerability of HB0034 in healthy subjects following a single dose or multiple dose.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-29.
Status change: Not Yet Recruiting → Recruiting 2025-01-16
Trial Details
NCT Number NCT06716151
Lead Sponsor Shanghai Huaota Biopharmaceutical Co., Ltd.
Conditions Healthy
Enrollment 60 participants
Start Date 2024-12-06
Primary Completion 2025-11-20 (estimated)
Study Completion 2025-11-20 (estimated)
Updated on ClinicalTrials.gov 2025-01-20